The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
This product will be manufactured at Lupin’s Pithampur facility In India
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The transaction is anticipated to close in the first quarter of 2022
A total of 8308 stores are open across India and medicines are priced at affordable rates
The first clinical trial is expected to commence in early 2022 both in Europe and the US
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Subscribe To Our Newsletter & Stay Updated
